Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?

Seminars in Dialysis

Volumn 24, Issue 3, 2011, Pages 272-274

  Carrion, Andres F ^a   Fabrizi, Fabrizio ^b   Martin, Paul ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

CHEMICALLY INDUCED DISORDER; EDITORIAL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; RENAL REPLACEMENT THERAPY;

ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; ERYTHROPOIETIN, RECOMBINANT; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RIBAVIRIN;

EID: 79959358422     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00851.x     Document Type: Editorial

References (26)

1. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20:1271-1277, 2004
2. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 5:1452-1461, 2005
3. Bruchfeld A, Wilczek H, Elinder CG: Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78:745-750, 2004
4. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP, Poynard T: Interferon for interferon naïve patients with chronic hepatitis C. Cochrane Database Syst Rev 2:CD000370, 2002
5. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
6. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432:922-924, 2004
7. Martin P, Jensen DM: Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 23:844-855, 2008
8. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ: Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53: 32-41, 2011
9. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR: Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 48:1033-1043, 2008
10. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R: High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41:275-279, 2005
11. Ghany MG, Strader DB, Thomas DL, Seef LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374, 2009
12. Kidney Disease: Improving Global Outcomes (KDIGO): KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 109:S1-S99, 2008
13. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L: Evidence that plasma concentration rather than dose on per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 11:84-87, 2004
14. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132:103-112, 2007
15. De Franceschi L, Farrovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31:997-1004, 2000
16. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB: ITPA gene variations protect against anemia in patients treated for chronic hepatitis C. Nature 464:405-408, 2010
17. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A: The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 46:768-774, 2007
18. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC: Pegylated interferon alfa-2a (40 kD) and ribavirin in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 23:721-725, 2008
19. Bruchfeld A, Stahle L, Andersson J, Schvarcz R: Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 8:287-292, 2001
20. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B: Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16:193-195, 2001
21. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36:1831-1834, 2004
22. Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W: HCV response in patients with end stage renal disease treated with combination pegylated interferon α-2a and ribavirin. J Clin Gastroenterol 43:477-481, 2009
23. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT: Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 31:295-302, 2008
24. Lippi G, Franchini M, Favaloro E: Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 36:537-549, 2010
25. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ; PROVE1 Study Team: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827-1838, 2009
26. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open label, randomised, multicentre phase 2 trial. Lancet 376:705-716, 2010